THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 47 filers reported holding THESEUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $699,750 | +5.1% | 75,000 | 0.0% | 0.03% | +8.0% |
| Q1 2023 | $666,000 | +33.7% | 75,000 | -25.0% | 0.02% | +31.6% |
| Q4 2022 | $498,000 | -14.1% | 100,000 | 0.0% | 0.02% | -20.8% |
| Q3 2022 | $580,000 | +4.9% | 100,000 | 0.0% | 0.02% | +9.1% |
| Q2 2022 | $553,000 | -52.0% | 100,000 | 0.0% | 0.02% | -45.0% |
| Q1 2022 | $1,153,000 | -9.1% | 100,000 | 0.0% | 0.04% | -2.4% |
| Q4 2021 | $1,268,000 | – | 100,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,585,346 | $31,837,872 | 23.54% |
| Lynx1 Capital Management LP | 761,258 | $6,759,971 | 5.64% |
| Omega Fund Management, LLC | 711,479 | $6,317,934 | 4.12% |
| Orbimed Advisors | 17,233,668 | $153,034,972 | 3.00% |
| Fairmount Funds Management LLC | 1,865,671 | $16,567,158 | 2.85% |
| Nextech Invest Ltd. | 611,310 | $5,428,433 | 2.27% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $19,963,963 | 1.44% |
| VR Adviser, LLC | 770,000 | $6,837,600 | 1.34% |
| Opaleye Management Inc. | 488,100 | $4,334,328 | 1.30% |
| Paradigm Biocapital Advisors LP | 1,505,327 | $13,367,304 | 1.27% |